bluebird bio
NEWS
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
Davidson is one of three new executives to join Cambridge, Mass.-based Tessera.
The FDA-approved ide-cel, which will be marketed under the brand name Abecma is going to be the second therapy for myeloma. Here’s everything you need to know.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
Although the beginning of March was fairly slow, the end of the month shows a busy schedule for PDUFA dates for the U.S. FDA. Read on to see what’s on the calendar for this week.
Another bluebird bio executive is jumping ship. Chief Medical Officer David Davidson is leaving the company on April 16.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
The European Medicines Agency has launched a safety review of bluebird bio’s thalassaemia drug Zynteglo, a conditionally licensed gene therapy in Europe.
JOBS
IN THE PRESS
Data from pivotal KarMMa study to be presented at ASCO21 show 24.8-month median overall survival in triple-class exposed multiple myeloma
bluebird bio, Inc . (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM) will be presented during EHA2021 Virtual, the 26 th Annual Congress of the European Hematology Association, taking place June 9-17, 2021.
bluebird bio, Inc. reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securities 2021 Health Care Conference, Thursday, May 13, at 9:30 am ET 2021 RBC Capital Markets Global Healthcare Conference, Wednesday, May 19, at 1:55 pm ET
PsiOxus Therapeutics, Ltd., a clinical stage oncology company re-programming the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. presented preclinical data at the American Association for Cancer Research Annual Meeting 2021.
Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and Drug Administration has approved Abecma as the first B-cell maturation antigen -directed chimeric antigen receptor T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
90% of evaluable patients (27/30) alive and free of major functional disabilities (MFDs) at two years follow-up in Phase 2/3 Starbeam study (ALD-102)
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD bluebird bio has initiated process with regulators to resume clinical studies Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST
bluebird bio, Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.
bluebird bio, Inc. announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m. ET.